Abata Therapeutics Announces FDA Clearance of Investigational New Drug Application for Clinical Evaluation of ABA-101 in Progressive Multiple Sclerosis
Harnessing regulatory T cells to establish immune tolerence
Preclinical Development of a T Cell Receptor Engineered Regulatory T Cell (Treg) Therapy for Progressive Pathology in MS
Functional Characterization of Regulatory T cell (Treg) Therapy for the Treatment of Type 1 Diabetes (T1D)
Unveiling Novel T-cell Receptors (TCRs) for Enhanced Treg Cell Therapy in Type 1 Diabetes (T1D)
Are Cellular Therapies the Future of Autoimmune Disease?
Abata Therapeutics to Present and Participate in Upcoming Investor and Industry Events